CCM
DMRA

Connective Capital Management’s Damora Therapeutics DMRA Stock Holding History

Connective Capital Management’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-26,956
Closed -$100K – 69
2025
Q3 		$100K Buy
+26,956
New +$91.3K 0.09% 65

Other funds holding DMRA

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JG
Jain Global New York $25.4B AUM 45.67% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.97B AUM 32.34% 1-Year Est. Return

Connective Capital Management's DMRA Position: Q4 2025 in Review

Connective Capital Management sold out of Damora Therapeutics (DMRA) in Q4 2025, closing a stake of 26,956 shares — an estimated $100K sold.

Connective Capital Management first reported a position in DMRA in Q3 2025 and held it in 1 quarter. The position peaked at $100K in Q3 2025. 18 funds tracked by Wall St. Rank hold DMRA as of Q4 2025.

  • Connective Capital Management reported no remaining Damora Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Connective Capital Management sold 26,956 Damora Therapeutics shares in Q4 2025, an estimated $100K.
  • Connective Capital Management first reported a position in Damora Therapeutics in Q3 2025 and held it in 1 quarter.
  • Connective Capital Management's Damora Therapeutics position peaked at $100K in Q3 2025.
  • 18 funds tracked by Wall St. Rank held Damora Therapeutics as of Q4 2025.

Based on Connective Capital Management's 13F filing for Q4 2025, filed 19 Feb 2026.